Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Notebook From Japan: After The Earthquake

This article was originally published in PharmAsia News

Executive Summary

Following the earthquake and resulting tsunami that rocked Northern Japan March 11, PharmAsia News has published more than 50 articles on how biopharma and medical device companies are dealing with the financial, infrastructure, manufacturing and distribution impacts of the disaster

You may also be interested in...



Japanese Relief Effort Tracks Blood Pressure In Evacuees Remotely

WASHINGTON - Several mobile health technology vendors joined together earlier this year to sponsor a cardiovascular disease prevention program for evacuees who survived the devastating March 11 earthquake and tsunami in Japan

Japanese Relief Effort Tracks Blood Pressure In Evacuees Remotely

WASHINGTON - Several mobile health technology vendors joined together earlier this year to sponsor a cardiovascular disease prevention program for evacuees who survived the devastating March 11 earthquake and tsunami in Japan

Japan To Pass Bill For Special Economic Zones To Boost Foreign Investment And Consumer Confidence

TOKYO - Japan's Diet will pass legislation June 20 to create special economic zones in Northern Japan as part of the reconstruction effort from the March 11 earthquake and ensuing tsunami and nuclear crisis. While the specifics for the economic zones have yet to be settled, it is expected that substantial tax breaks will be included in the incentives to encourage reconstruction and foreign investment

Related Content

UsernamePublicRestriction

Register

SC078226

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel